{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:17:51Z","timestamp":1784726271959,"version":"3.55.0"},"reference-count":76,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>The emergence of new systemic treatments for alopecia areata underscores the importance of estimating rates of potential treatment safety events among individuals with alopecia areata. In this population-based cohort study, data linked across Danish population-based registries were used to examine the rates of the following safety events of interest before approval of Janus kinase inhibitor treatments by the European Medicines Agency: serious infections, herpes zoster infections, malignancies, arterial and venous cardiovascular events, and all-cause death in an alopecia areata cohort, defined as individuals \u2265\u200912 years old with hospital-treated alopecia areata, including its sub-types alopecia totalis and alopecia universalis. Incidence rates of the safety events of interest were computed and their associations with alopecia areata were estimated as standardized incidence ratios computed with regard to the age- and sex-matched general Danish population. The alopecia areata cohort included 2,778 individuals (472 with alopecia totalis\/alopecia universalis) with a first-recorded diagnosis of alopecia areata in 1995\u20132016, followed through to the end of 2016, during a hospital admission or treatment at an outpatient clinic. Hospital-treated alopecia areata was associated with serious infections (standardized incidence ratio [95% confidence interval], 1.89 [1.72\u20132.06]), herpes zoster infections (1.83 [1.63\u20132.05]), lymphoma (3.44 [1.88\u20135.77]), arterial and venous cardiovascular outcomes (1.41 [1.12\u20131.75]), and death (1.16 [1.00\u20131.34]).<\/jats:p>","DOI":"10.2340\/actadv.v105.42646","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:12:19Z","timestamp":1747368739000},"page":"adv42646","source":"Crossref","is-referenced-by-count":2,"title":["Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark"],"prefix":"10.2340","volume":"105","author":[{"given":"Sissel Brandt Toft","family":"S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prethibha","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladayo","family":"Jagun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Napatalung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel H.","family":"Zwillich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Ehrenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"111549","doi-asserted-by":"crossref","unstructured":"Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata: current understanding and management. J Dtsch Dermatol Ges 2022; 20: 59\u201390.","DOI":"10.1111\/ddg.14689"},{"key":"111550","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14689","DOI":"10.1111\/ddg.14689"},{"key":"111551","unstructured":"Al Aboud AM, Syed HA, Zito PM. Alopecia. [Updated 2024 Feb 26] In: StatPearls [Internet] [cited 2024, 24 June]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538178\/."},{"key":"111552","doi-asserted-by":"crossref","unstructured":"Muntyanu A, Gabrielli S, Donovan J, Gooderham M, Guenther L, Hanna S, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol 2023; 37: 1490\u20131520.","DOI":"10.1111\/jdv.18926"},{"key":"111553","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18926","DOI":"10.1111\/jdv.18926"},{"key":"111554","doi-asserted-by":"crossref","unstructured":"Ly S, Manjaly P, Kamal K, Shields A, Wafae B, Afzal N, et al. Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis. Am J Clin Dermatol 2023; 24: 875\u2013893.","DOI":"10.1007\/s40257-023-00805-4"},{"key":"111555","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-023-00805-4","DOI":"10.1007\/s40257-023-00805-4"},{"key":"111556","unstructured":"(EMA) EMA. Olumiant (baricitinib) 2023 [cited 2023, 05 November]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant."},{"key":"111557","unstructured":"(EMA) EMA. Litfulo (ritlecitinib) 2023 [cited 2023, 05 November]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/litfulo."},{"key":"111558","doi-asserted-by":"crossref","unstructured":"King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol 2023; 188: 218\u2013227.","DOI":"10.1093\/bjd\/ljac059"},{"key":"111559","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljac059","DOI":"10.1093\/bjd\/ljac059"},{"key":"111560","doi-asserted-by":"crossref","unstructured":"King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol 2024; 25: 299\u2013314.","DOI":"10.1007\/s40257-024-00846-3"},{"key":"111561","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-024-00846-3","DOI":"10.1007\/s40257-024-00846-3"},{"key":"111562","doi-asserted-by":"crossref","unstructured":"Papierzewska M, Waskiel-Burnat A, Rudnicka L. Safety of Janus kinase inhibitors in patients with alopecia areata: a systematic review. Clin Drug Investig 2023; 43: 325\u2013334.","DOI":"10.1007\/s40261-023-01260-z"},{"key":"111563","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40261-023-01260-z","DOI":"10.1007\/s40261-023-01260-z"},{"key":"111564","doi-asserted-by":"crossref","unstructured":"Chen Y, Zhu H, Shen Y, Zhu Y, Sun J, Dai Y, et al. Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis. J Dermatolog Treat 2022; 33: 3143\u20133149.","DOI":"10.1080\/09546634.2022.2133956"},{"key":"111565","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2022.2133956","DOI":"10.1080\/09546634.2022.2133956"},{"key":"111566","doi-asserted-by":"crossref","unstructured":"Chim I, Ghiya R, Sinclair RD, Eisman S. Novel investigational drugs for alopecia areata and future perspectives. Expert Opin Investig Drugs 2024; 33: 441\u2013449.","DOI":"10.1080\/13543784.2024.2348062"},{"key":"111567","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/13543784.2024.2348062","DOI":"10.1080\/13543784.2024.2348062"},{"key":"111568","doi-asserted-by":"crossref","unstructured":"Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2019; 58: i34\u2013i42.","DOI":"10.1093\/rheumatology\/key287"},{"key":"111569","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/rheumatology\/key287","DOI":"10.1093\/rheumatology\/key287"},{"key":"111570","doi-asserted-by":"crossref","unstructured":"Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv -Musculoskelet Dis 2020; 12: 1759720X20936059.","DOI":"10.1177\/1759720X20936059"},{"key":"111571","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1759720X20936059","DOI":"10.1177\/1759720X20936059"},{"key":"111572","doi-asserted-by":"crossref","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017; 13: 320.","DOI":"10.1038\/nrrheum.2017.51"},{"key":"111573","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrrheum.2017.51","DOI":"10.1038\/nrrheum.2017.51"},{"key":"111574","doi-asserted-by":"crossref","unstructured":"Kang JH, Lin HC, Kao S, Tsai MC, Chung SD. Alopecia areata increases the risk of stroke: a 3-year follow-up study. Sci Rep 2015; 5: 11718.","DOI":"10.1038\/srep11718"},{"key":"111575","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/srep11718","DOI":"10.1038\/srep11718"},{"key":"111576","doi-asserted-by":"crossref","unstructured":"Sorensen SBT, George P, Jagun O, Wolk R, Napatalung L, Zwillich SH, et al. The epidemiology of hospital-treated alopecia areata in Denmark, 1995\u20132016. Dermatol Ther (Heidelb) 2024; 14: 993\u20131006.","DOI":"10.1007\/s13555-024-01145-9"},{"key":"111577","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-024-01145-9","DOI":"10.1007\/s13555-024-01145-9"},{"key":"111578","doi-asserted-by":"crossref","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundboll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 2019; 11: 563\u2013591.","DOI":"10.2147\/CLEP.S179083"},{"key":"111579","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S179083","DOI":"10.2147\/CLEP.S179083"},{"key":"111580","doi-asserted-by":"crossref","unstructured":"Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29: 541\u2013549.","DOI":"10.1007\/s10654-014-9930-3"},{"key":"111581","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10654-014-9930-3","DOI":"10.1007\/s10654-014-9930-3"},{"key":"111582","doi-asserted-by":"crossref","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449\u2013490.","DOI":"10.2147\/CLEP.S91125"},{"key":"111583","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S91125","DOI":"10.2147\/CLEP.S91125"},{"key":"111584","doi-asserted-by":"crossref","unstructured":"Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39: 42\u201345.","DOI":"10.1177\/1403494810393562"},{"key":"111585","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1403494810393562","DOI":"10.1177\/1403494810393562"},{"key":"111586","doi-asserted-by":"crossref","unstructured":"Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011; 39: 26\u201329.","DOI":"10.1177\/1403494811399958"},{"key":"111587","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1403494811399958","DOI":"10.1177\/1403494811399958"},{"key":"111588","doi-asserted-by":"crossref","unstructured":"Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT. Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 2012; 4: 303\u2013313.","DOI":"10.2147\/CLEP.S37587"},{"key":"111589","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S37587","DOI":"10.2147\/CLEP.S37587"},{"key":"111590","doi-asserted-by":"crossref","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 2023; 401: 1518\u20131529.","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"111591","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-2","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"111592","doi-asserted-by":"crossref","unstructured":"Holland-Bill L, Xu H, Sorensen HT, Acquavella J, Svaerke C, Gammelager H, et al. Positive predictive value of primary inpatient discharge diagnoses of infection among cancer patients in the Danish National Registry of Patients. Ann Epidemiol 2014; 24: 593\u20137, 97 e1\u201318.","DOI":"10.1016\/j.annepidem.2014.05.011"},{"key":"111593","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annepidem.2014.05.011","DOI":"10.1016\/j.annepidem.2014.05.011"},{"key":"111594","doi-asserted-by":"crossref","unstructured":"Akyea RK, Leonardi-Bee J, Asselbergs FW, Patel RS, Durrington P, Wierzbicki AS, et al. Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models. BMJ Open 2020; 10: e034564.","DOI":"10.1136\/bmjopen-2019-034564"},{"key":"111595","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2019-034564","DOI":"10.1136\/bmjopen-2019-034564"},{"key":"111596","unstructured":"Breslow NE, Day NE. Statistical methods in cancer research. Volume II: The design and analysis of cohort studies. IARC Sci Publ 1987: 1\u2013406."},{"key":"111597","doi-asserted-by":"crossref","unstructured":"Zaaroura H, Gilding AJ, Sibbald C. Biomarkers in alopecia areata: a systematic review and meta-analysis. Autoimmun Rev 2023; 22: 103339.","DOI":"10.1016\/j.autrev.2023.103339"},{"key":"111598","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103339","DOI":"10.1016\/j.autrev.2023.103339"},{"key":"111599","doi-asserted-by":"crossref","unstructured":"Glickman JW, Dubin C, Renert-Yuval Y, Dahabreh D, Kimmel GW, Auyeung K, et al. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol 2021; 84: 370\u2013380.","DOI":"10.1016\/j.jaad.2020.04.138"},{"key":"111600","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.138","DOI":"10.1016\/j.jaad.2020.04.138"},{"key":"111601","doi-asserted-by":"crossref","unstructured":"George P, Jagun O, Liu Q, Wentworth C, Napatalung L, Wolk R, et al. Incidence rates of infections, malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US Claims Database. Dermatol Ther (Heidelb) 2023; 13: 1733\u20131746.","DOI":"10.1007\/s13555-023-00937-9"},{"key":"111602","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-023-00937-9","DOI":"10.1007\/s13555-023-00937-9"},{"key":"111603","doi-asserted-by":"crossref","unstructured":"Chen CC, Chang YT, Liu HN, Chen YJ. Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study. Cancer Med 2018; 7: 2153\u20132159.","DOI":"10.1002\/cam4.1448"},{"key":"111604","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.1448","DOI":"10.1002\/cam4.1448"},{"key":"111605","doi-asserted-by":"crossref","unstructured":"Miller R, Conic RZ, Bergfeld W, Mesinkovska NA. Prevalence of comorbid conditions and sun-induced skin cancers in patients with alopecia areata. J Investig Dermatol Symp Proc 2015; 17: 61\u201362.","DOI":"10.1038\/jidsymp.2015.44"},{"key":"111606","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jidsymp.2015.44","DOI":"10.1038\/jidsymp.2015.44"},{"key":"111607","doi-asserted-by":"crossref","unstructured":"Mostaghimi A, Qureshi S, Joyce C, Guo Y, Huang KP. Reduced incidence of skin cancer in patients with alopecia areata: a retrospective cohort study. Cancer Epidemiol 2016; 41: 129\u2013131.","DOI":"10.1016\/j.canep.2016.02.009"},{"key":"111608","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.canep.2016.02.009","DOI":"10.1016\/j.canep.2016.02.009"},{"key":"111609","doi-asserted-by":"crossref","unstructured":"Kridin K, Laufer-Britva R, Jimenez F, Cohen AD, Kaplan B, Lyakhovitsky A. Alopecia areata and malignancies: uncertainties clarified by a large-scale population-based study. Arch Dermatol Res 2024; 316: 678.","DOI":"10.1007\/s00403-024-03385-3"},{"key":"111610","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00403-024-03385-3","DOI":"10.1007\/s00403-024-03385-3"},{"key":"111611","doi-asserted-by":"crossref","unstructured":"Schneeweiss MC, Kim SC, Wyss R, Jin Y, Chin K, Merola JF, et al. Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases. JAMA Dermatol 2021; 157: 805\u2013816.","DOI":"10.1001\/jamadermatol.2021.1570"},{"key":"111612","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.1570","DOI":"10.1001\/jamadermatol.2021.1570"},{"key":"111613","doi-asserted-by":"crossref","unstructured":"Huang KP, Joyce CJ, Topaz M, Guo Y, Mostaghimi A. Cardiovascular risk in patients with alopecia areata (AA): a propensity-matched retrospective analysis. J Am Acad Dermatol 2016; 75: 151\u2013154.","DOI":"10.1016\/j.jaad.2016.02.1234"},{"key":"111614","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1234","DOI":"10.1016\/j.jaad.2016.02.1234"},{"key":"111615","doi-asserted-by":"crossref","unstructured":"Sundboll J, Adelborg K, Munch T, Froslev T, Sorensen HT, Botker HE, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 2016; 6: e012832.","DOI":"10.1136\/bmjopen-2016-012832"},{"key":"111616","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2016-012832","DOI":"10.1136\/bmjopen-2016-012832"},{"key":"111617","doi-asserted-by":"crossref","unstructured":"Adelborg K, Sundboll J, Munch T, Froslev T, Sorensen HT, Botker HE, et al. Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study. BMJ Open 2016; 6: e012817.","DOI":"10.1136\/bmjopen-2016-012817"},{"key":"111618","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2016-012817","DOI":"10.1136\/bmjopen-2016-012817"},{"key":"111619","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen LK, Dalgaard LS, \u00d8stergaard LJ, Andersen NS, N\u00f8rgaard M, Mogensen TH. Validity of the coding for herpes simplex encephalitis in the Danish National Patient Registry. Clin Epidemiol 2016; 8: 133\u2013140.","DOI":"10.2147\/CLEP.S104379"},{"key":"111620","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S104379","DOI":"10.2147\/CLEP.S104379"},{"key":"111621","doi-asserted-by":"crossref","unstructured":"Egeberg A, Anderson S, Edson-Heredia E, Burge R. Comorbidities of alopecia areata: a population-based cohort study. Clin Exp Dermatol 2021; 46: 651\u2013656.","DOI":"10.1111\/ced.14507"},{"key":"111622","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.14507","DOI":"10.1111\/ced.14507"},{"key":"111623","doi-asserted-by":"crossref","unstructured":"Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol 2023; 159: 411\u2013418.","DOI":"10.1001\/jamadermatol.2023.0002"},{"key":"111624","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.0002","DOI":"10.1001\/jamadermatol.2023.0002"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/42646\/50126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/42646\/50126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:13:10Z","timestamp":1747368790000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/42646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":76,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.42646","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}